SCHEMBL13795430

SCHEMBL13795430

COCCNc1nc(NC[C@H]2CC[C@H](CNS(=O)(=O)c3ccc(C)cc3)CC2)nc2ccccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 11/20 0.62
▸ SLC6A4 P31645 2/20 0.54
▸ HMOX1 P09601 1/20 0.52
▸ ALDH1A1 P00352 3/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ADRA2A P08913 6/20 0.49
▸ MCHR1 Q99705 5/20 0.49
▸ AQP1 P29972 2/20 0.49
▸ MAPT P10636 2/20 0.49
▸ HPGD P15428 1/20 0.49
▸ NPY1R P25929 1/20 0.49
▸ NPY2R P49146 1/20 0.49
▸ NPY4R P50391 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ PDE5A O76074 1/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ MEN1 O00255 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13796628 0.94 NPY5R (0.55) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL13796664 0.92 NPY5R (0.53) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL13795408 0.92 NPY5R (0.53) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL14606698 0.91 NPY5R (0.54) NPY5RSLC6A4HMOX1ALDH1A1ADRA2A
SCHEMBL13796765 0.90 NPY5R (0.53) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL13796444 0.90 NPY5R (0.69) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL13796334 0.89 NPY5R (0.64) NPY5RSLC6A4HMOX1ALDH1A1ADRA2A
SCHEMBL13795920 0.89 NPY5R (0.64) NPY5RSLC6A4HMOX1ALDH1A1ADRA2A
SCHEMBL13796815 0.88 NPY5R (0.52) NPY5RSLC6A4ALDH1A1ADRA2AMCHR1
SCHEMBL13796657 0.87 NPY5R (0.66) NPY5RSLC6A4HMOX1ALDH1A1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544690-B2 MCH receptor antagonists TAISHO PHARMACEUTICAL CO., LTD. (JP) 2009-06-09 — — US disclosed
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide TAISHO PHARMACEUTICAL CO., LTD. (JP) 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037836-A1 Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide MCHR1, MCHR2, MC4R NPY5R 11/4885SLC6A4 73/4885HMOX1 683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback